Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prediction Intervals01:03

Prediction Intervals

3.4K
The interval estimate of any variable is known as the prediction interval. It helps decide if a point estimate is dependable.
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y. 
3.4K
Constraints and Statical Determinacy01:26

Constraints and Statical Determinacy

1.0K
In structural engineering, the equilibrium of a system is not only determined by its equations of equilibrium but also with the help of constraints. Constraints refer to restrictions on the motion of a system. The proper combinations of constraints can minimize the total number of constraints needed to maintain a system in mechanical equilibrium. When this happens, the system is said to be statically determinate. For such systems, the unknown reaction supports can be estimated using equilibrium...
1.0K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

250
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
250
Confidence Intervals01:21

Confidence Intervals

10.8K
An unbiased point estimate is often insufficient to predict a population estimate, such as population mean or population proportion. In this scenario, a confidence interval is used. A confidence interval is an estimate similar to a  sample proportion. However, unlike the point estimate which is a single value, the confidence interval  contains a range of values. These values have lower and upper limits, known as confidence limits, and can be designated as L1 and L2, respectively.
A...
10.8K
Improper Integrals: Infinite Intervals01:29

Improper Integrals: Infinite Intervals

110
An integral is classified as improper due to an infinite interval when at least one of its limits of integration extends to positive or negative infinity. In such cases, the region under the curve is unbounded, and standard techniques for evaluating definite integrals are not directly applicable. Instead, the improper integral is defined through a limiting process that allows one to determine whether the accumulated area remains finite despite the infinite domain.Application to Exponential...
110
Group Design02:01

Group Design

10.7K
The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same author

Two-Stage Double-Arm Trial Optimal Design of Restricted Mean Survival Time With Sculpted Critical Region.

Statistics in medicine·2026
Same author

BAR12: Bayesian Autoregressive Phase 1-2 Design for Cell Therapy Trials With Manufacturing Changes.

Statistics in medicine·2026
Same author

Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Bayesian Integrated Learning of Longitudinal Dose-Response Relationships via Decentralized Clinical Trials.

Statistics in medicine·2025
Same author

Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019.

Blood advances·2025
Same journal

Statistical analysis of disease onset during lifespan with left truncation.

Biometrics·2026
Same journal

Interim analysis in sequential multiple assignment randomized trials for survival outcomes.

Biometrics·2026
Same journal

Acknowledgment of Referees 2025.

Biometrics·2026
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
See all related articles

Related Experiment Video

Updated: Feb 9, 2026

Design and Optimization Strategies of a High-Performance Vented Box
14:23

Design and Optimization Strategies of a High-Performance Vented Box

Published on: June 9, 2023

1.6K

Bayesian optimal interval design with multiple toxicity constraints.

Ruitao Lin1,2

  • 1Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, U.S.A.

Biometrics
|June 6, 2018
PubMed
Summary
This summary is machine-generated.

This study introduces a new Bayesian optimal interval (BOIN) design for phase I clinical trials to manage multiple drug toxicity outcomes. The enhanced method accurately controls various toxicity types and grades, improving drug safety assessment.

Keywords:
Dose findingInterval designMaximum tolerated doseMinimax ruleMultiple outcomesToxicity grade

More Related Videos

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
09:12

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

1.2K
Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry
09:15

Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry

Published on: July 26, 2019

10.0K

Related Experiment Videos

Last Updated: Feb 9, 2026

Design and Optimization Strategies of a High-Performance Vented Box
14:23

Design and Optimization Strategies of a High-Performance Vented Box

Published on: June 9, 2023

1.6K
Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
09:12

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

1.2K
Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry
09:15

Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry

Published on: July 26, 2019

10.0K

Area of Science:

  • Clinical Pharmacology
  • Biostatistics
  • Drug Development

Background:

  • Phase I dose-finding trials traditionally focus on single binary toxicity outcomes.
  • Distinguishing between various toxicity types and grades is crucial for comprehensive drug safety evaluation.
  • Existing methods may not adequately address complex multi-toxicity scenarios in early-phase drug trials.

Purpose of the Study:

  • To extend the Bayesian optimal interval (BOIN) design for controlling multiple toxicity outcomes in phase I trials.
  • To develop a robust and efficient design that handles equally important, unequally important, and nested toxicity outcomes.
  • To provide a practical and accurate method for assessing drug safety with multiple toxicity endpoints.

Main Methods:

  • Developed a multiple-toxicity Bayesian optimal interval (BOIN) design by minimizing the maximum joint probability of incorrect decisions.
  • The design accommodates various importance levels and relationships (nested) among toxicity outcomes.
  • Extended the methodology to address trials involving combined drug therapies.

Main Results:

  • The multiple-toxicity BOIN design effectively controls multiple toxicity outcomes at prespecified levels.
  • For non-nested outcomes, optimal interval boundaries align with the standard single-toxicity BOIN design when treated marginally.
  • Simulations demonstrate the proposed methods are accurate, efficient, robust, and easier to implement than complex model-based approaches.

Conclusions:

  • The multiple-toxicity BOIN design offers a significant advancement for phase I dose-finding trials.
  • This approach enhances the ability to manage complex safety profiles of new drugs.
  • The design provides a practical and reliable tool for optimizing drug development and patient safety.